FDA Approves First Freeze-Dried Plasma Product for Emergency Use

The U.S. Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma (FDP), marking a significant advancement in the availability of blood products for critical situations. This marks the first time a freeze-dried plasma product has received FDA approval in the United States. Ezplaz is designed for transfusion in adult patients requiring plasma, particularly in circumstances where conventional frozen plasma is not readily accessible.

The development of Ezplaz addresses a critical need for faster access to plasma in remote or emergency settings. Patients experiencing severe bleeding in combat zones, disaster areas, or rural locations could benefit from this new product when standard frozen plasma is unavailable. This innovation is expected to be particularly impactful for military personnel and individuals in areas lacking immediate access to traditional medical infrastructure.

Ezplaz is a freeze-dried plasma product derived from a single unit of fresh frozen plasma. It is available in Group AB and Group A with low-titer anti-B blood types. These specific blood types were chosen to reduce the risk of adverse reactions when administering the product in emergency situations before a patient’s blood type is definitively known.

A key advantage of Ezplaz over conventional plasma products is its storage and reconstitution capabilities. Unlike frozen plasma, which requires thawing before use, Ezplaz can be stored at room temperature and remains stable even with temperature fluctuations. It can be rapidly reconstituted for administration. Furthermore, it is packaged in a plastic bag instead of a glass bottle, which enhances its durability and reduces the likelihood of breakage during transport and handling. These characteristics make Ezplaz suitable for use in austere environments, including potential combat zones, remote locations, and disaster response scenarios.

The intended use of Ezplaz is for transfusion in adult patients who require plasma and for whom other plasma products are not available. This includes patients with bleeding conditions, those undergoing massive transfusions, and certain patients on warfarin who are experiencing bleeding. Each Ezplaz kit is a comprehensive package that includes a unit of freeze-dried plasma, sterile water for injection, and sets for fluid transfer and blood transfusion.

The FDA’s review process confirmed that the benefits of Ezplaz transfusion outweigh the associated risks, with a safety profile consistent with other transfused plasma products. However, as with all plasma products, healthcare providers and patients should be aware of potential transfusion risks and review the full prescribing information prior to use. The biologics license for Ezplaz was granted to Vascular Solutions, LLC, a subsidiary of Teleflex. This licensure also reflects a collaborative effort under Public Law 115-92, which supports the development and review of products for serious conditions affecting military personnel.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

Video Spotlight